243 related articles for article (PubMed ID: 35973139)
21. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
[TBL] [Abstract][Full Text] [Related]
22. Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty.
Kochar BD; Cai W; Ananthakrishnan AN
Dig Dis Sci; 2022 Feb; 67(2):622-628. PubMed ID: 33932198
[TBL] [Abstract][Full Text] [Related]
23. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
24. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease-A Cohort Study.
Madsen KG; Pottegård A; Hallas J; Kjeldsen J
Inflamm Bowel Dis; 2018 Nov; 24(12):2628-2633. PubMed ID: 29788214
[TBL] [Abstract][Full Text] [Related]
25. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
26. Increased risk of pneumonia among patients with inflammatory bowel disease.
Long MD; Martin C; Sandler RS; Kappelman MD
Am J Gastroenterol; 2013 Feb; 108(2):240-8. PubMed ID: 23295276
[TBL] [Abstract][Full Text] [Related]
27. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
28. Associations Between Obesity and the Effectiveness of Anti-Tumor Necrosis Factor-α Agents in Inflammatory Bowel Disease Patients: A Literature Review and Meta-analysis.
Dai ZH; Xu XT; Ran ZH
Ann Pharmacother; 2020 Aug; 54(8):729-741. PubMed ID: 31955605
[No Abstract] [Full Text] [Related]
29. Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease.
Yang JY; Lund JL; Funk MJ; Hudgens MG; Lewis JD; Kappelman MD;
Am J Gastroenterol; 2023 Sep; 118(9):1638-1647. PubMed ID: 37053548
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
31. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
32. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Singh S; Facciorusso A; Dulai PS; Jairath V; Sandborn WJ
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):69-81.e3. PubMed ID: 30876964
[TBL] [Abstract][Full Text] [Related]
33. Safety and Efficacy of Vedolizumab Versus Tumor Necrosis Factor α Antagonists in an Elderly IBD Population: A Single Institution Retrospective Experience.
Pabla BS; Alex Wiles C; Slaughter JC; Scoville EA; Dalal RL; Beaulieu DB; Schwartz DA; Horst SN
Dig Dis Sci; 2022 Jul; 67(7):3129-3137. PubMed ID: 34268660
[TBL] [Abstract][Full Text] [Related]
34. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy.
Hasan B; Tandon KS; Miret R; Khan S; Riaz A; Gonzalez A; Rahman AU; Charles R; Narula N; Castro FJ
J Gastroenterol Hepatol; 2022 Jun; 37(6):1016-1021. PubMed ID: 35191100
[TBL] [Abstract][Full Text] [Related]
35. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and epidemiology of overweight and obesity in children with inflammatory bowel disease.
Long MD; Crandall WV; Leibowitz IH; Duffy L; del Rosario F; Kim SC; Integlia MJ; Berman J; Grunow J; Colletti RB; Schoen BT; Patel AS; Baron H; Israel E; Russell G; Ali S; Herfarth HH; Martin C; Kappelman MD;
Inflamm Bowel Dis; 2011 Oct; 17(10):2162-8. PubMed ID: 21910178
[TBL] [Abstract][Full Text] [Related]
37. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
38. Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.
Cheng D; Kochar B; Cai T; Ritchie CS; Ananthakrishnan AN
Am J Gastroenterol; 2022 Nov; 117(11):1845-1850. PubMed ID: 35854436
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
Alrashed F; Abdullah I; Alfadhli A; Shehab M
Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
[No Abstract] [Full Text] [Related]
40. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study.
Holmer AK; Luo J; Russ KB; Park S; Yang JY; Ertem F; Dueker J; Nguyen V; Hong S; Zenger C; Axelrad JE; Sofia A; Petrov JC; Al-Bawardy B; Fudman DI; Llano E; Dailey J; Jangi S; Khakoo N; Damas OM; Barnes EL; Scott FI; Ungaro RC; Singh S;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1598-1606.e5. PubMed ID: 36642291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
